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Introduction. Acute self-poisoning with the organophosphorus (OP) pesticide dimethoate has a human case fatality three-fold higher than
poisoning with chlorpyrifos despite similar animal toxicity. The typical clinical presentation of severe dimethoate poisoning is quite distinct
from that of chlorpyrifos and other OP pesticides: many patients present with hypotension that progresses to shock and death within 12–48 h
post-ingestion. The pathophysiology of this syndrome is not clear. Case reports. We present here three patients with proven severe
dimethoate poisoning. Clinically, all had inappropriate peripheral vasodilatation and profound hypotension on presentation, which
progressed despite treatment with atropine, i.v. fluids, pralidoxime chloride, and inotropes. All died 2.5–32 h post-admission. Continuous
cardiac monitoring and quantification of troponin T provided little evidence for a primary cardiotoxic effect of dimethoate. Conclusion.
Severe dimethoate self-poisoning causes a syndrome characterized by marked hypotension with progression to distributive shock and death
despite standard treatments. A lack of cardiotoxicity until just before death suggests that the mechanism is of OP-induced low systemic
vascular resistance (SVR). Further invasive studies of cardiac function and SVR, and post-mortem histology, are required to better describe
this syndrome and to establish the role of vasopressors and high-dose atropine in therapy.
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Introduction
Self-poisoning with organophosphorus (OP) insecticides is
a major clinical problem across rural Asia (1), killing an
estimated 200,000 people every year (2,3). Most deaths
result from respiratory failure, because of the acute cholin-
ergic crisis, complications of pre-hospital pesticide aspira-
tion, and late onset neuromuscular junction failure (4).
However, in a large cohort of OP pesticide-poisoned
patients (5), we have noted patients with dimethoate poison-
ing on adequate ventilatory support dying from cardiovas-
cular complications, in particular severe hypotension.
Previous reports on cardiac complications of OP poisoning
have focused on dysrhythmias (6–11) and hypertension
(12,13) with hypotensive effects being relatively less fre-
quently reported(14–17).
Hypotension is a particularly important cause of death in
dimethoate poisoning. Over 40% of patients dying from
dimethoate poisoning present with a systolic blood pressure
(BP) of less than 80 mmHg (compared to 5% of patients dying
from chlorpyrifos poisoning) (18). Such patients have a case
fatality in excess of 80%. In this article, we describe the clinical
features of severe dimethoate poisoning in three patients treated
in an under-resourced rural district hospital in Sri Lanka.
Case Reports
Case 1
A 55-year-old male presented with cholinergic features after
intentionally ingesting an unknown quantity of dimethoate
with alcohol. On arrival, he had a pulse of 60 beats/min,
blood pressure (BP) 90/60 mmHg, respiratory rate of 5 breaths/
min, and Glasgow Coma Scale (GCS) 3/15. Examination
revealed a hyperdynamic pulse and apex beat, normal heart
sounds, marked peripheral vasodilatation (Fig. 1), and normal
capillary refill time. Widespread wheeze and crepitations
were present in both lungs, and pulse oximetry showed an
oxygen saturation of 60% despite oxygen at 10 L/min. He
was intubated, ventilated, and given boluses of atropine (to a
total of 8 mg), and his oxygen saturation improved to 96% on
6 L/min of oxygen. An atropine infusion was then started at
0.5 mg/h, and he received pralidoxime chloride 1 g i.v. fol-
lowed by 1 g q6h. Two hours after admission, he had normal
breath sounds on auscultation and clear lung fields on chest
radiograph.
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He was commenced on dopamine 10 mcg/kg/min 5 h after
admission when his BP became refractory to further fluid
challenges with normal saline (Fig. 2). Nineteen hours post-
admission, his BP deteriorated to 45/20 mmHg despite dou-
bling the dopamine to 20 mcg/kg/min. He was given 500 mcg
epinephrine and started on dobutamine at 10 mcg/kg/min in
addition to dopamine (norepinephrine and vasopressin were
not available in the hospital). There was a clear response in BP
to the addition of dobutamine. By this time, he had developed
marked subconjunctival and peripheral edema. His urine out-
put remained >50 mL/h apart from the first 2 h after admission.
Six hours later, his BP fell again despite further fluid chal-
lenges totaling 4 L of 0.9% saline plus 10 mg of atropine and
increased infusions of dopamine (30 mcg/kg/min) and dob-
utamine (40 mcg/kg/min). The decline was irreversible and
he had a pulseless electrical activity (PEA) cardiac arrest 32 h
post-admission from which he did not recover despite admin-
istration of epinephrine and atropine.
Blood samples taken 22 h after admission showed the creatine
kinase to be elevated (12,640 U/L; Table 1); this was accompa-
nied by rises in aspartate aminotransferase and lactate dehydroge-
nase but not troponin T. Renal biochemistry was normal. His
cardiac rhythm was continuously recorded using a Holter moni-
tor. It showed a sinus tachycardia throughout, with normal com-
plexes up until about 30 min prior to his final cardiac arrest, when
there was evidence of T wave inversion and ST depression.
Fig. 1. Peripheral vasodilatation in patients 1 and 2 while
hypotensive on admission. Both photographs were taken when the
patients were supine with BPs of 85/35 mmHg (top, case 1) and 55/
30 mmHg (bottom, case 2), respectively.
Fig. 2. Clinical course of patient 1. The top half of the figure
shows heart rate, mean arterial pressure (•) together with systolic
and diastolic arterial pressures (↕), and oxygen saturations. The
bottom half of the figure shows the infusion rates of both
dopamine and dobutamine.
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Table 1. Dimethoate concentration, butyrylcholinesterase activity,
and cardiac enzymes in the three study patients
Case 1 2 3
Time after admission 40 min 22 h 45 min 30 min
Dimethoate 
concentration (μM)
1,177 438 1,670 1,619
BuChE (mU/mL) 455 134 431 442
CK (U/L; RR 40–180) 43 12,640 109 ND
Tn T (ng/mL; RR <0.09) 0.00 0.03 0.00 ND
BuChE, butyrylcholinesterase (plasma pseudocholinesterase); CK, creat-
ine kinase; ND, not done; RR, reference range; Tn T, troponin T.
Plasma was separated from an EDTA blood sample and frozen at –20°C.
BuChE activity was assayed as described (30,31). The median (IQR)
BuChE activity in this population is 4,500 (3,200–5,200) mU/mL (Eyer,
unpublished). Plasma dimethoate concentrations were quantified by
reversed phase HPLC and UV detection (lower limit of quantitation 1
nmol/mL plasma). CK and Tn T were assayed in a clinical laboratory.Clinical Toxicology vol. 46 no. 9 2008
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Case 2
A 50-year-old male presented 3.5 h after ingesting an
unknown quantity of dimethoate showing cholinergic fea-
tures. He was rapidly intubated but immediately had a PEA
cardiac arrest from which he was resuscitated with 3 mg atro-
pine and 1 mg epinephrine. His ECG then showed sinus
rhythm with ventricular ectopics. On subsequent examina-
tion, he had marked peripheral vasodilatation with distended
superficial veins (Fig. 1), normal heart sounds, and an undis-
placed apex beat. Auscultation of the lungs revealed bilateral
wheeze and crepitations that improved with atropine. His
oxygen saturation was normal following atropine and
entrained oxygen at 6 L/min within half an hour of his initial
cardiac arrest.
Three hours after admission he had a second PEA cardiac
arrest from which he could not be resuscitated despite boluses
of epinephrine and atropine. Prior to this, we were unable to
maintain his BP above 60/35 mmHg despite administering
4 L 0.9% saline, 13 mg of atropine, and dopamine at 70 mcg/
kg/min. He had continued to pass urine during this time.
Case 3
A 54-year-old male presented 2 h after intentionally ingesting
an unknown amount of dimethoate. On arrival, he showed
cholinergic features, had a pulse of 41 beats/min, BP 70/40
mmHg, GCS 3/15, pinpoint pupils, and respiratory rate of
6 breaths/min. He was given oxygen and atropine, and rap-
idly intubated. He responded poorly to atropine (total >200 mg,
in boluses of up to 50 mg), becoming more hypotensive and
bradycardic, until he had a PEA cardiac arrest in sinus
rhythm 30 min after admission. He was resuscitated with
boluses of epinephrine totaling 4 mg and given pralidoxime
chloride 1 g.
Over the next 2 h his BP and heart rate fell on several occa-
sions and he was given a total of 18 mg epinephrine (equiva-
lent to around 3.3 mcg/kg/min). His response to increasing
doses of epinephrine diminished and he died from a PEA car-
diac arrest 2.5 h post-admission.
Discussion
We present here three cases of proven severe dimethoate self-
poisoning that resulted in progressive hypotension and death
despite administration of standard antidotes, fluid resuscita-
tion, large doses of inotrope/vasopressor agents, and adequate
ventilatory support. Because of the lack of evidence for bene-
fit (19,20), gastric decontamination was not performed for
any patient. None of the patients had any previous history of
cardiac disease or co-morbidity. These three patients provide
more detailed description of the hypotensive syndrome previ-
ously reported (5). Such a clear clinical syndrome has not
been reported for other OPs and its pathophysiology is
unclear.
We have previously reported two cases of OP-induced
hypotension with substantially reduced systemic vascular
resistance (SVR) after dimethoate or fenthion poisoning (14).
However, both patients had pre-existing vascular disease.
Other authors have reported four patients (two with
malathion and two with fenitrothion) that died from hypoten-
sive shock (16). Further, a patient with severe hypotension
after combined malathion and fenitrothion poisoning was
successfully treated with extracorporeal cardiopulmonary
support (15). The responsible OP was not confirmed analyti-
cally in any case.
This hypotensive syndrome may result from the very high
plasma concentrations of OP noted, which may reflect the
relatively low lipid solubility of dimethoate (log Kow 0.76
(21)) (and therefore limited and slow tissue distribution)
compared with other OP agents (5). However, as mentioned
above, severe hypotension has been reported in some patients
reporting ingestion of highly fat-soluble OPs such as fenthion
(log Kow 4.30 (21)) and fenitrothion (log Kow 3.37 (21)).
Our experience in Sri Lanka is that severe hypotension is rare
in fenthion poisoning (5). If the syndrome is largely because
of the persistent very high blood concentrations in dimethoate
poisoning, we would predict it to also occur commonly with
methamidophos and oxydemeton methyl, both OPs with
expected limited tissue distribution due to low log Kow val-
ues less than 1.0 (21).
Alternatively, the toxicity may reflect co-formulants in the
EC (22) preparation. These compounds include emulsifiers or
surfactants, and organic solvents such as cyclohexanone and
xylene. The cardiotoxic effect of the surfactants used in gly-
phosate herbicide is the best recognized example of co-for-
mulant toxicity (23,24). However, the situation with organo-
phosphorus EC insecticides is less clear with a sparse litera-
ture on their co-formulants. Furthermore, each company has
its own formula for the EC preparation using different (often
patented) solvents and emulsifiers.
The solvent is unlikely to be responsible for the
dimethoate-specific syndrome as the majority of generic OP
insecticide products available in Sri Lanka use 40% xylene as
their solvent base (5). In particular, the solvent does not usu-
ally differ between chlorpyrifos and dimethoate despite their
different syndromes. We have also found a very clear rela-
tionship between plasma dimethoate concentration and out-
come in Sri Lankan patients (25). As the patients have
ingested different brands of dimethoate, with different emul-
sifiers and other co-formulants, it seems unlikely that they
can be primarily responsible for dimethoate EC40’s toxicity.
Animal experiments to directly address the relative toxicity
of dimethoate active ingredient and formulated dimethoate
insecticide will likely be needed to answer the question and
are currently underway (Eddleston & Clutton, unpublished).
Possible pathophysiological mechanisms include a primary
cardiotoxic effect (26) or peripheral vasodilatation causing a
distributive shock (14) or a mixed picture. We saw no evi-
dence of direct cardiotoxicity – the cholinergic bradycardia was
readily reversed with atropine, there was no rise in troponin T,Clinical Toxicology vol. 46 no. 9 2008
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and a Holter monitor in one patient showed normal sinus
rhythm until just before death. ECGs taken from cases 1 and
2 showed no QT or QRS prolongation. Fluid loss did not play
a major role – atropine rapidly reversed the muscarinic fea-
tures of poisoning, controlling fluid loss. All patients contin-
ued to pass urine at good rates until death.
Animal studies have demonstrated multiple mechanisms of
toxicity that may lead to hypotension in acute OP poisoning.
OPs cause peripheral vasodilatation via the effect of acetyl-
choline on muscarinic receptors on vascular endothelium.
They may also block nicotinic transmission at sympathetic
and parasympathetic ganglia, leading to inhibition of the
baroreceptor reflexes. Animal studies have also suggested
that chronic OP exposure may cause oxidative damage of the
vascular endothelium (27). One study has suggested that mast
cell-mediated effects (anaphylaxis) may occur after OP poi-
soning (28), potentially leading to histamine-induced
hypotension.
The patients presented here were treated in under-
resourced hospitals similar to the hospitals that treat most OP
cases globally. Resources for direct measurement of SVR and
cardiac output were not available. However, clinical observa-
tion suggested that peripheral vasodilatation and distributive
shock are likely to be the main mechanisms. The patients had
marked peripheral vasodilatation on admission (Fig. 1)
despite severe hypotension that was not apparently linked
with right heart failure. We were struck by the relative brady-
cardia that accompanied the marked hypotension, likely
resulting from overwhelming cholinergic stimulation and
therefore slowing of the heart in the context of reduced SVR.
Treatment with atropine reversed the bradycardia (Fig. 2).
Buckley and colleagues (14) previously recommended giv-
ing very high doses of atropine, rather than inotropes, to treat
OP-induced hypotension. However, case 3 (and many other
cases in the cohort (5)) received over 200 mg of atropine
soon after admission without effect on their BP. Unfortu-
nately, norepinephrine was not available at this hospital, as
studies of septic shock suggest that it might have been effec-
tive when the patients became refractory to dopamine (29).
However, Asari and colleagues (16) found no effect of nore-
pinephrine administration in four OP cases. Similarly, Kam-
ijo and colleagues (15) found no benefit from a dopamine
infusion in their patient and were forced to initiate extracor-
poreal life support. Case 3 in this series died despite large
doses of epinephrine but he was so unwell on arrival to hospi-
tal that it was unlikely that he would have responded to any
combination of inotropes.
Large case series with proven exposure to other OPs are
required to determine whether the syndrome occurs with
other pesticides and whether the extent of hypotension is
inversely proportional to the lipid solubility. Future studies
must include direct assessment of cardiac output and SVR in
previously fit patients to define this syndrome more accu-
rately and improve management. Further evidence is also
required on the effectiveness of vasopressors and anticholin-
ergic drugs.
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